Introduction
============

Although hepatitis B virus (HBV) vaccine is widely used, HBV infection remains a main cause of hepatic cirrhosis and hepatocellular carcinoma ([@ref-4]). Among 2 billion people infected with HBV, 350 million individuals develop chronic HBV infection ([@ref-11]). Over 8% of Chinese, Southeast Asian, and African populations are hepatitis B surface antigen (HBsAg)-positive ([@ref-23]), so HBV infection is still a serious problem in these populations. Genetic factors influence HBV-infection and treatment effects of HBV-infected individuals ([@ref-6]; [@ref-9]; [@ref-24]). Understanding the role of host genetic variations in HBV infection, pathogenesis, and therapy is important to provide individualized protection and treatment for HBV-infected cases.

Interleukin 28B (IL28B) belongs to the interferon *λ* family, which is a new interferon family. Genetic variations of the *IL28B* gene have been identified to be associated with HCV infection, viral clearance, and response to therapy ([@ref-19]; [@ref-20]; [@ref-21]; [@ref-25]). However, genome-wide association studies (GWAS) in Asian population found that *IL28B* gene is not correlated with HBV infection or viral clearance ([@ref-8]; [@ref-7]). [@ref-8] identified that genetic variants in the HLA-DP locus are strongly associated with risk of persistent HBV infection. Subsequently, two new gene loci (HLA-C and UBE2L3) have been highlighted to play important roles in the clearance of HBV infection ([@ref-7]). However, the single nucleotide polymorphisms (SNPs) or the haplotypes constructed by SNPs in the *IL28B* gene can influence the HBV infection, HBV surface antigen seroclearance, or treatment of HBV-infected individuals in special cohorts ([@ref-14]; [@ref-3]). SNPs [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860) and [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917) were mostly studied and identified to be associated with HBV-infection in Chinese ([@ref-1]). Until now, we found no study was performed to reveal the relationship of genetic polyporphisms in the *IL28B* of HBV-infected persons and biochemical characteristics. The purpose of this study is to investigate whether SNPs in the *IL28B* gene influence the HBV infection and biochemical characteristics of HBV-infected individuals in Yunnan, China.

Materials and Methods
=====================

Subjects
--------

All HBV-infected individuals and age- and gender-matched controls were recruited by doctors in the First People's Hospital of Yunnan Province. In our previous study, basic information, biochemical characteristics, and HBV serological markers of each subject were reported ([@ref-15]). In brief, the liver function test (alanine transaminease (ALT), aspartate transaminase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL), total protein (TP), albumin (ALB), and globin (GLOB)), renal function (blood urea nitrogen (BUN), serum creatinine (CREA), serum uric acid (UA), and blood glucose (GLU)), and part of blood routine (white blood cells (WBC), neutrophilic granulocyte (NEUT), lymphocytes (LYM), monocytes (MONO), eosinophil granulocyte (EO), and basophile granulocyte (BASO)) were measured (all data has been reported in our previous study ([@ref-15])). All individuals were Han Chinese. In this study, whole blood samples (3 mL) of 493 HBV-infected individuals (274 males and 219 females) and 460 controls (285 males and 175 females) were collected. All HBV-infected individuals and controls were not infected with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and *Treponema pallidum*. All controls were devoid of HBV, HCV, or HIV infection, and no seriously hepatitic disease (hepatic fibrosis, Hepatocellular Carcinoma, and so forth) were identified in controls. The mean ages of the individuals in the HBV-infected and control cohorts were 41.5 ± 0.3 and 38.8 ± 0.3 years (mean ± SEM), respectively. HBV-infected individuals were also without other serious liver disease. Written informed consent conforming to the tenets of the Declaration of Helsinki was obtained from each participant prior to the study. This study was approved by the Institutional Review Board of Kunming University of Science and Technology (Approval No. 2014SK027).

Genomic DNA extraction and genotyping
-------------------------------------

Genomic DNA was extracted from whole blood by using the TIANamp genomic DNA Kit (TIANGEN, China). Three SNPs (i.e.,  [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860), [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917), and [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275)) in the *IL28B* gene were selected and analyzed as reference-described ([@ref-1]). Genotypes of each SNP were screened by using the SnapShot assay ([Table S1](#supp-1){ref-type="supplementary-material"}). SnapShot is based on single-base extension. In brief, amplifying and extending primers for each SNP are firstly designed. Then PCR reaction is performed with two kinds of primers and will be terminated behind one base of 3′  end of extending primers. Finally, genotypes of each SNP are determined according to fluorescence color. Genotyping results of 10% total samples were verified by sequencing. Haplotypes were constructed using Phase software for further analysis ([@ref-17]).

Subgrouping of HBV-infected individuals
---------------------------------------

According to the subgrouping principle in our previous study ([@ref-15]), HBV-infected individuals were divided into three groups. Group \#1 included patients who with HbsAg and HBeAg positive were at acute infected phase (*N* = 29). Group \#2 included patients with HBsAg and anti-HBc positive, who were at chronic infected phase (*N* = 202). Patients in group \#3 were comprised of HBV-infected individuals undergoing convalescence (*N* = 262), who were anti-HBc positive but HBV DNA negative.

Quantification of the HBV viral load
------------------------------------

HBV DNA was extracted from the serum of each sample by using the TIANamp Virus DNA/RNA Kit (TIANGEN, China). The HBV viral load in the serum of 58 HBV-infected individuals was detected by using the Hepatitis B Viral DNA Quantitative Fluorescence Diagnostic Kit (realtime-PCR-Fluorescence Probing) (Sansure, Hunan, China) in accordance with the manufacturer's instructions and ABI 7500 Fast Real-Time PCR system (Applied Biosystems, USA). Results were recorded in International Unit (IU)/mL; one IU/mL was equivalent to 5.6 copies/mL. The lowest detection limitation of this quantitative method was 2,800 copies/mL (500 IU/mL). In further analysis, HBV DNA was log10-transformed, i.e., the lowest detection limitation was 3.45 log10 copies/mL.

Data analysis
-------------

The Hardy--Weinberg equilibrium (HWE) was assessed in each variant to evaluate the deviation of collected cohorts. Given that the numbers of a genotype of each SNP were less than five, 1,000 iterations for simulation were performed. The Chi-square test was collected to analyze the frequency of genotypes and alleles between the different cohorts. Student's *t*-test (unpaired, two tails) was used to compare HBV viral load between the two HBV-infected groups and biochemical characteristics among the HBV-infected individuals with different genotypes. Biochemical characteristics in the groups are presented as mean ± SEM. Correlation analysis was used to analyze the relationship between viral loads and LYM levels. Statistical significance was considered at *P* \< 0.05.

Results
=======

No deviation was found in the HBV-infected individuals and controls after calculating HWE, and these results suggested that the analyzed population was in genetic equilibrium. Genotype and allele frequency showed no significant difference between the HBV-infected individuals and general controls ([Table 1](#table-1){ref-type="table"}). The genotyping data are listed in [Tables S2](#supp-2){ref-type="supplementary-material"} and [S3](#supp-3){ref-type="supplementary-material"} ([Table S2](#supp-2){ref-type="supplementary-material"} for HBV-infected patients and [Table S3](#supp-3){ref-type="supplementary-material"} for controls). Seven and five haplotypes constructed by three SNPs were identified in the HBV-infection group and controls, respectively. Although the haplotypes were somewhat different between two groups, the frequency of each haplotype showed no significant difference ([Table 2](#table-2){ref-type="table"}).
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###### Genotype and allele frequency of three SNPs of the *IL28B* gene in HBV-infected individuals and controls.

![](peerj-05-4149-g002)

  SNP (genotype/allele)                                            HBV-infected individual (*N* = 493)              Controls (*N* = 460)   *P*-value[^b^](#table-1fn2){ref-type="fn"}   OR             95% CI         
  ---------------------------------------------------------------- ------------------------------------------------ ---------------------- -------------------------------------------- -------------- -------------- --------------
  [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860)   HWE[^a^](#table-1fn1){ref-type="fn"}*P* = 1.00   HWE *P* = 0.79                                                                                    
  Genotype                                                         CC                                               439                    400                                          0.320          1.219          0.824--1.804
  CT                                                               52                                               57                     0.372                                        0.834          0.559--1.243   
  TT                                                               2                                                3                      0.599                                        0.621          0.103-3.730    
  Allele                                                           C                                                930                    857                                          0.292          1.221          0.842--1.771
  T                                                                56                                               63                     0.819                                        0.565--1.188                  
  [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917)     HWE *P* = 1.00                                   HWE *P* = 1.00                                                                                    
  Genotype                                                         GG                                               1                      2                                            0.523          0.465          0.042--5.151
  GT                                                               49                                               52                     0.494                                        0.866          0.573--1.308   
  TT                                                               443                                              406                    0.429                                        1.178          0.784--1.771   
  Allele                                                           G                                                51                     56                                           0.386          0.842          0.570--1.244
  T                                                                935                                              864                    1.188                                        0.804--1.756                  
  [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275)   HWE *P* = 0.78                                   HWE *P* = 0.50                                                                                    
  Genotype                                                         AA                                               437                    398                                          0.321          1.216          0.826--1.788
  AG                                                               55                                               58                     0.488                                        0.870          0.588--1.298   
  GG                                                               1                                                4                      0.155                                        0.232          0.026--2.081   
  Allele                                                           A                                                929                    854                                          0.216          1.260          0.873--1.817
  G                                                                57                                               66                     0.794                                        0.550--1.145                  

**Notes.**

Chi-square test for deviation from the Hardy--Weinberg equilibrium (a value of *P* \< 0.01 was regarded as a deviation from the HWE).

Chi-square test was used.
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###### Haplotypes constructed by three SNPs in HBV-infected individuals and controls.

![](peerj-05-4149-g003)

  Haplotype                                 HBV-infected individuals (*N* = 493)   Controls (*N* = 460)   *P*-value[^b^](#table-2fn2){ref-type="fn"}   OR      95% CI
  ----------------------------------------- -------------------------------------- ---------------------- -------------------------------------------- ------- --------------
  CTA                                       925                                    853                    0.339                                        1.191   0.832--1.706
  TGG                                       46                                     55                     0.201                                        0.770   0.515--1.151
  TTG                                       7                                      7                      0.896                                        0.933   0.326--2.669
  Others[^a^](#table-2fn1){ref-type="fn"}   8                                      5                      0.478                                        1.497   0.488--4.592

**Notes.**

Means those haplotypes which frequency is less than 0.5%.

Chi-square test was used.
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###### Genotype and allele frequency in three groups of HBV-infected individuals.

![](peerj-05-4149-g004)

  SNP (genotype/allele)                                            Group \#1 (*N* = 29)   Group \#2 (*N* = 202)   Group \#3 (*N* = 262)   Group \#1 v.s. group \#2[^a^](#table-3fn1){ref-type="fn"}*P*-value (OR, 95% CI)[^b^](#table-3fn2){ref-type="fn"}   Group \#1 v.s. group \#3 *P*-value (OR, 95% CI)   Group \#2 v.s. group \#3 *P*-value (OR, 95% CI)   
  ---------------------------------------------------------------- ---------------------- ----------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------- ------------------------------------------------- -----------------------------
  [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860)                                                                                                                                                                                                                                                                                                 
  Genotype                                                         CC                     24                      178                     237                                                                                                                0.415 (0.647, 0.226--1.856)                       0.196 (0.506, 0.178--1.444)                       0.416 (0.782, 0.432--1.415)
  CT                                                               5                      22                      25                      0.320 (1.705, 0.590--4.922)                                                                                        0.196 (1.975, 0.693--5.632)                       0.633 (1.159, 0.633--2.121)                       
  TT                                                               0                      2                       0                       0.590 (--)                                                                                                         1.000 (--)                                        0.107 (--)                                        
  Allele                                                           C                      53                      378                     499                                                                                                                0.534 (0.729, 0.268--1.981)                       0.208 (0.531, 0.195--1.445)                       0.270 (1.373, 0.780--2.416)
  T                                                                5                      26                      25                      0.534 (1.372, 0.505--3.726)                                                                                        0.208 (1.883, 0.692--5.124)                       0.270 (0.728, 0.414--1.282)                       
  [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917)                                                                                                                                                                                                                                                                                                   
  Genotype                                                         GG                     0                       1                       0                                                                                                                  0.704 (--)                                        1.000 (--)                                        0.254 (--)
  GT                                                               6                      21                      22                      0.107 (2.248, 0.822--6.147)                                                                                        0.033 (2.846, 1.048--7.728)                       0.462 (1.266, 0.675--2.372)                       
  TT                                                               23                     180                     240                     0.131 (0.469, 0.172--1.276)                                                                                        0.033 (0.351, 0.129--0.954)                       0.363 (0.750, 0.403--1.397)                       
  Allele                                                           G                      6                       23                      22                                                                                                                 0.172 (1.911, 0.744--4.913)                       0.038 (2.633, 1.022--6.786)                       0.293 (1.377, 0.756--2.509)
  T                                                                52                     381                     502                     0.172 (0.523, 0.204--1.345)                                                                                        0.038 (0.380, 0.147--0.979)                       0.293 (0.726, 0.399--1.322)                       
  [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275)                                                                                                                                                                                                                                                                                                 
  Genotype                                                         AA                     24                      177                     236                                                                                                                0.466 (0.678, 0.237--1.939)                       0.226 (0.529, 0.186--1.504)                       0.402 (0.780, 0.436--1.397)
  AG                                                               5                      24                      26                      0.415 (1.545, 0.539--4.431)                                                                                        0.226 (1.891, 0.665--5.378)                       0.500 (1.224, 0.680--2.203)                       
  GG                                                               0                      1                       0                       0.704 (--)                                                                                                         1.000 (--)                                        0.254 (--)                                        
  Allele                                                           A                      53                      378                     498                                                                                                                0.534 (0.729, 0.268--1.981)                       0.239 (0.553, 0.204--1.502)                       0.333 (0.759, 0.434--1.329)
  G                                                                5                      26                      26                      0.534 (1.372, 0.505--3.726)                                                                                        0.239 (1.807, 0.666--4.903)                       0.333 (1.317, 0.753--2.306)                       

**Notes.**

Chi-square test was used to calculate the *P*-value.

OR and 95% CI mean Odds ratio and Confidence interval, respectively.

HBV-infected individuals were divided into three subgroups according to HBV serological markers of patients. Excluding the genotype and allele frequency of SNP [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917) between groups \#1 and \#3, we identified no other significant difference ([Table 3](#table-3){ref-type="table"}). The genotype GT of [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917) showed a statistically higher frequency in group \#1 (20.69%, 6/29) than in group \#3 (8.40%, 22/262) (*P* = 0.033), whereas the genotype TT of [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917) showed a significantly low frequency in group \#1 (*P* = 0.033). The frequencies of allele G were 10.34% and 4.20% in patients of group \#1 and of group \#3, respectively. Hence, allele G likely seemed the risk factor for patient in group \#1 ([Table 3](#table-3){ref-type="table"}).

Given that the patients in group \#3 underwent convalescence, HBV DNA viral load cannot be detected in this study. The HBV viral loads of 14 acutely and 44 chronic HBV-infected individuals were tested. The results showed that HBV viral load of the acutely HBV-infected individuals was higher than that of the chronic HBV-infected group (*P* = 0.0003) ([Fig. 1](#fig-1){ref-type="fig"}). The viral loads of the patients with different genotypes of each SNP were similar in groups \#1 and \#2.

![Quantification of viral load in acute or chronic HBV-infected individuals.\
Each sample is represented by one circle (for acute HBV-infected individuals) or one square (for chronic HBV-infected individuals). The middle line in each group represents the mean number of the HBV viral load, together with standard error of the group.](peerj-05-4149-g001){#fig-1}

Considering that the frequencies of genotype CC of [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860), GG of [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917), and GG of 12980275 were minor in our two cohorts (HBV-infected individuals and controls), we pooled genotypes CC and CT of [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860), genotypes GG and GT of [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917), and genotypes GG and AG of [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275) for further biochemical characteristics analysis ([Table 4](#table-4){ref-type="table"}). Results showed that leukomonocyte (LYM) levels existed discrepancies between two groups of SNPs [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860) and [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275). The LYM levels of the HBV-infected individuals with genotype CC of [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860) (*P* = 0.032) and genotype AA of [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275) (*P* = 0.034) were significantly lower than that of the patients with pooled genotypes. No correlation was found between HBV viral load and LYM level.
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###### Analysis of biochemical characteristics of genotypes of each SNP in HCV-infected persons.

![](peerj-05-4149-g005)

  Marker   [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860) (Mean ± SEM)   Marker         [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860) (Mean ±  SEM)                                         
  -------- ----------------------------------------------------------------------------- -------------- ------------------------------------------------------------------------------ ------ -------------- --------------- -------
  AST      38.86 ± 4.29                                                                  32.41 ± 4.04   0.598                                                                          BUN    5.15 ± 0.19    4.42 ± 0.16     0.168
  ALT      48.16 ± 7.46                                                                  36.02 ± 5.22   0.566                                                                          CREA   81.78 ± 5.94   63.09 ± 2.08    0.269
  TBIL     14.77 ± 0.91                                                                  12.85 ± 0.73   0.460                                                                          UA     344.9 ± 5.05   338.7 ± 13.48   0.683
  DBIL     6.48 ± 0.71                                                                   4.68 ± 0.36    0.371                                                                          WBC    9.26 ± 2.47    7.00 ± 0.36     0.749
  IBIL     8.28 ± 0.26                                                                   8.18 ± 0.44    0.890                                                                          NEUT   4.39 ± 0.13    4.36 ± 0.35     0.939
  TP       72.90 ± 0.37                                                                  72.89 ± 0.87   0.993                                                                          LYM    1.78 ± 0.03    2.00 ± 0.10     0.032
  ALB      40.54 ± 0.29                                                                  40.69 ± 0.70   0.865                                                                          MONO   0.42 ± 0.01    0.45 ± 0.03     0.333
  GLOB     32.36 ± 0.26                                                                  32.20 ± 0.66   0.843                                                                          EO     0.15 ± 0.01    0.12 ± 0.01     0.255
  GLU      4.90 ± 0.07                                                                   4.61 ± 0.10    0.152                                                                          BASO   0.03 ± 0.001   0.03 ± 0.003    0.948

  Marker   [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917) (Mean ± SEM)   Marker         [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917) (Mean ± SEM)                                         
  -------- --------------------------------------------------------------------------- -------------- --------------------------------------------------------------------------- ------ --------------- -------------- -------
  AST      31.48 ± 3.92                                                                38.91 ± 4.26   0.557                                                                       BUN    4.43 ± 0.16     5.15 ± 0.19    0.198
  ALT      36.68 ± 5.60                                                                47.98 ± 7.39   0.606                                                                       CREA   64.40 ± 2.26    81.46 ± 5.88   0.329
  TBIL     13.69 ± 0.96                                                                14.66 ± 0.90   0.719                                                                       UA     347.8 ± 14.26   343.8 ± 5.02   0.799
  DBIL     4.93 ± 0.40                                                                 6.44 ± 0.70    0.471                                                                       WBC    6.89 ± 0.32     9.25 ± 2.45    0.747
  IBIL     8.86 ± 0.63                                                                 8.21 ± 0.25    0.481                                                                       NEUT   4.31 ± 0.27     4.40 ± 0.13    0.827
  TP       73.16 ± 0.90                                                                72.87 ± 0.37   0.797                                                                       LYM    1.98 ± 0.10     1.79 ± 0.03    0.075
  ALB      41.04 ± 0.66                                                                40.50 ± 0.29   0.544                                                                       MONO   0.46 ± 0.03     0.42 ± 0.01    0.186
  GLOB     32.12 ± 0.68                                                                32.37 ± 0.26   0.760                                                                       EO     0.12 ± 0.02     0.15 ± 0.01    0.264
  GLU      4.55 ± 0.09                                                                 4.90 ± 0.07    0.091                                                                       BASO   0.03 ± 0.003    0.03 ± 0.001   0.903

  Marker   [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275) (Mean ± SEM)   Marker         [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275) (Mean ± SEM)                                         
  -------- ----------------------------------------------------------------------------- -------------- ----------------------------------------------------------------------------- ------ -------------- --------------- -------
  AST      38.92 ± 4.31                                                                  32.20 ± 3.89   0.577                                                                         BUN    5.16 ± 0.19    4.43 ± 0.16     0.166
  ALT      48.29 ± 7.49                                                                  35.48 ± 5.05   0.539                                                                         CREA   81.89 ± 5.96   62.95 ± 1.92    0.255
  TBIL     14.75 ± 0.92                                                                  13.09 ± 0.72   0.517                                                                         UA     345.5 ± 5.13   334.3 ± 11.71   0.454
  DBIL     6.49 ± 0.71                                                                   4.70 ± 0.34    0.368                                                                         WBC    9.27 ± 2.48    6.97 ± 0.34     0.741
  IBIL     8.25 ± 0.26                                                                   8.40 ± 0.44    0.847                                                                         NEUT   4.39 ± 0.13    4.34 ± 0.34     0.895
  TP       72.85 ± 0.38                                                                  73.27 ± 0.83   0.669                                                                         LYM    1.78 ± 0.03    2.00 ± 0.10     0.034
  ALB      40.50 ± 0.29                                                                  40.96 ± 0.69   0.585                                                                         MONO   0.42 ± 0.01    0.45 ± 0.03     0.384
  GLOB     32.35 ± 0.27                                                                  32.30 ± 0.62   0.956                                                                         EO     0.15 ± 0.01    0.12 ± 0.01     0.341
  GLU      4.90 ± 0.07                                                                   4.64 ± 0.10    0.194                                                                         BASO   0.03 ± 0.001   0.03 ± 0.002    0.859

**Notes.**

Student *t* test (unpaired, two-tail) was used.

Discussion
==========

IL28B plays an important role in HCV infection and fateful hepatic diseases caused by HCV ([@ref-13]; [@ref-22]). Although no association exists between HBV infection and genetic polymorphisms in the *IL28B* gene by GWAS, the *IL28B* gene could influence the viral clearance and treatment effect in different HBV-infected populations ([@ref-16]). In the present study, we analyzed the genotype and allele frequency of SNPs in the *IL28B* gene, district phases of HBV infection, HBV viral load, and biochemical characteristics of HBV-infected individuals.

SNPs [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860), [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917), and [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275) were frequently studied in HBV-infected populations ([@ref-10]; [@ref-12]). Although analysis results were not confident, the important role of *IL28B* could not be neglected. In the present study, we did not identify the association between the genotypes and alleles of three SNPs and HBV infection. However, the genotypes of [rs8099917](http://www.ncbi.nlm.nih.gov/snp/?term=rs8099917) were likely different between HBV-infected individuals under the acute infected phase and convalescence. This result suggested that genetic variations of the *IL28B* gene might influence HBV-infected phase. Considering that the HBV viral load was detected in only 58 HBV-infected individuals, we did not identify the association between HBV viral load and SNP genotypes in the *IL28B* gene. However, polymorphisms of the *IL28B* gene were reportedly associated with HBV viral load and liver inflammation ([@ref-10]). HBV-infected sample size should be amplified for further study.

Genetic polymorphisms in the *IL28B* gene were reported not to affect HBV viral clearance in HBV-infected or HBV/HIV-coinfected persons ([@ref-18]). Although the effect of the *IL28B* gene is unclear in HBV/HCV-coinfected persons, HBV viral load and/or viral clearance might be influenced ([@ref-2]) because of the affirmatory role of *IL28B* in HCV infection ([@ref-5]; [@ref-21]). To exclude the effect of coinfection, we selected persons infected by HBV only and confirmed that genetic variations of the *IL28B* gene might relate to the pathogenesis of HBV infection and biochemical characteristics of HBV-infected individuals.

HBV viral load was detected in 58 HBV-infected individuals, including 14 acutely and 44 chronic infectious patients. The viral load was significantly higher in acute infectious group than in chronic group. However, no association was found between HBV viral load and genetic variations in the *IL28B* gene. Similarly, no correlation was found between HBV viral load and LYM level. These results suggested that the association between genetic polymorphisms and LYM might not be influenced by HBV viral load. Whether HBV genotype played a special role in the association needs further study.

LYM is one of the most important immune cells, which main function is to recognize and clear the bacteria, virus, and tumor. When individuals are infected by virus, LYM will be activited and induce a series of immune response. Due to the lack of analysis between LYM level and genetic polymorphisms in HBV-infected patients, we firstly performed and identified that the LYM level showed significant difference between HBV patients with differ genotypes of SNPs [rs12979860](http://www.ncbi.nlm.nih.gov/snp/?term=rs12979860) and [rs12980275](http://www.ncbi.nlm.nih.gov/snp/?term=rs12980275). Although the results needs further verification, it would help us to explore the role of LYM in HBV infection.

Conclusion
==========

No association was found between genetic variations in the *IL28B* gene and HBV infection in Yunnan population. However, LYM level could be influenced by genetic variations in the *IL28B* gene in this study. Further complex analyses should focus in studying the relationship between host genetic factors, biochemical characteristics of HBV patients, HBV infection, HBV-infected process, HBV viral load, and HBV genotypes.
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